REGN stock premium vs fair value: Key data for 2025

Snapshot: what the data says right now

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is presented here with multiple market snapshots from 2025, alongside a valuation summary. One data block lists REGN at $159.18 with a stated fair value of $157.00, implying the stock is trading at a 614% premium. The same snapshot also flags uncertainty as “Medium” and provides a 1-Star Price of $146.20 and 5-Star Price of $149.00.

Alongside this valuation view, other price points appear in the provided text: $142.0 as on 03 Dec, 2025, $155.46 on 29 Oct, 2025 (noted as +$10.67, +12.08%), and a trading interface showing Sell $177.67 and Buy $182.48 on 25 Oct 2025. These figures come from different timestamps and contexts, so they should be read as separate snapshots rather than a single continuous quote.

Company profile and what Regeneron does

Regeneron Pharmaceuticals is described as a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines. It is also called a fully integrated biotechnology company, indicating it participates across the drug development and commercial lifecycle.

The text lists Regeneron’s focus areas as eye disease, cardiovascular disease, cancer, and inflammation, and also cites broader areas including allergic and inflammatory diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The company is headquartered in Tarrytown, New York, and its founding date is given as January 8, 1988.

Product portfolio mentioned in the dataset

Multiple marketed products and brands are explicitly named across the provided blocks. These include Eylea (including low-dose Eylea and Eylea HD), Dupixent, Praluent, Libtayo, and Kevzara. Additional brands listed include Evkeeza, Inmazeb, ARCALYST, and ZALTRAP.

The dataset also associates certain products with therapeutic areas. Eylea products are described as approved for wet age-related macular degeneration and other eye diseases. Dupixent is referenced in immunology, Praluent for LDL cholesterol lowering, Libtayo in oncology, and Kevzara in rheumatoid arthritis.

R&D approach and partnership references

Regeneron is described as accelerating traditional drug development through proprietary VelociSuite technologies, including VelocImmune, which uses genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.

On collaborations, the text states that Regeneron is developing monoclonal and bispecific antibodies with Sanofi, and it also references early-stage partnerships tied to new technology in the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia). No financial terms of these collaborations are provided in the input.

Valuation and trading metrics included

The valuation block contains a cluster of commonly tracked ratios and market statistics. It lists Market Cap: $10.81B, Price/Earnings (Normalized): 17.11, and Price/Sales: 5.75.

Income return data in the snapshot includes Dividend Yield (Trailing): 0.46% and Dividend Yield (Forward): 0.50%, along with Total Yield: 5.20%. The text also shows Volume/Avg: 173,684 / 977,346, suggesting the referenced day’s volume versus an average volume figure.

Price snapshots: what changed across the timestamps

The provided blocks show several discrete price points in October to December 2025. On 29 Oct 2025, REGN is shown at $155.46, with the same section stating the stock hit a high of $154.39 and low of $108.45 that day.

Another interface lists Sell $177.67 and Buy $182.48 on 25 Oct 2025 (prices delayed by at least 15 minutes, per the snippet). A separate quote line shows 578.05 with a +1.56% move and a post-market line at 19:50 EDT, again indicating a different market snapshot. Finally, a later point lists $142.0 as on 03 Dec, 2025.

Returns table: performance figures shown

A returns table is included for REGN with multiple time windows. It shows +10.05% over 1 year, +49.91% over 5 years, +8.43% 5-year annualized, and +3,475% since IPO. The table does not specify the exact end date for these return calculations.

What the India investor references indicate

The dataset explicitly says investors can buy Regeneron shares from India by opening an international trading account, and it also notes that if investing from India, it is useful to check the current exchange rate and convert the value into rupees. One block mentions access “from India at just ₹1 from Appreciate,” which appears as a platform claim in the provided text.

These references matter mainly for accessibility, not fundamentals. All other key figures shown in the dataset are denominated in USD, and the trading venue is explicitly stated as NASDAQ.

Key facts table (from the provided text)

Why this dataset is notable for investors

The central tension in the provided figures is the large gap between the stated fair value ($157.00) and the shown trading price ($159.18) in the valuation snapshot, described as a 614% premium with medium uncertainty. Separately, the text provides multiple price points across late October and early December 2025, indicating that the dataset is compiled from different screens or sources.

From a business perspective, the dataset emphasizes Regeneron’s marketed portfolio across ophthalmology, immunology, cardiovascular risk, and oncology, plus its antibody-development capabilities and collaborations. For Indian investors specifically, the most actionable detail in the text is the pathway mentioned for access - using an international trading account and considering USD-INR conversion before placing trades.

Conclusion

Regeneron (REGN) is presented as a fully integrated biotechnology company with several well-known brands and partnerships, while the valuation snapshot in the input shows the stock trading far above a stated fair value. The next practical step for readers is to verify the latest live quote and currency conversion, since the provided prices span multiple dates and contexts in 2025.